trial

Smoking Relapse Prevention in Schizophrenia

NCTId NCT00320697
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 25 (actual)
Sponsored by North Suffolk Mental Health Association
Primary completion 2008-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
25 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2006-04
Primary completion
2008-10
Eligibility
ALL · 18 Years · 70 Years

Interventions & indications

Drugs
bupropion + nicotine patch + nicotine gum or lozenges

Sponsors

North Suffolk Mental Health AssociationLead Sponsor

Investigators

1
A. Eden Evins, MD, MPHPrincipal Investigator

Sites

1 total
Boston, United States

Facts & assertions

4 sourced
Enrollment
25
Phase
PHASE4
Primary Completion Date
2008-10
Status
COMPLETED
relationships
The graph out of here
drug
bupropion + nicotine patch + nicotine gum or lozenges
drug
lead_sponsor
North Suffolk Mental Health Association
company
indication
Schizoaffective Disorder
indication
Smokers
indication
Psychotic Disorders
indication
investigator
A. Eden Evins, MD, MPH
person